{"filing":{"accession_number":"0001193125-26-429770","cik":"0000728387","ticker":"CATX","company_name":"Perspective Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"catx-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526429770/catx-20261023.htm"},"events":[{"id":37501,"run_id":34564,"accession_number":"0001193125-26-429770","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Perspective Therapeutics announced updated interim Phase 1/2a clinical trial results for [212Pb]VMT-α-NET presented at ESMO Congress 2026, showing encouraging efficacy (33–50% ORR across cohorts), durable disease control (72% PFS at 18 months), and favorable safety profile (no dose-limiting toxicities, no treatment discontinuations). The company is advancing toward Phase 3 site preparation with expected initiation in 2027. This is a material clinical development milestone for a radiopharmaceutical company with a single lead program, affecting investor assessment of pipeline progress and regulatory pathway viability.","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42235,"accession_number":"0001193125-26-429770","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Perspective Therapeutics announced updated interim Phase 1/2a clinical trial results for [212Pb]VMT-α-NET presented at ESMO Congress 2026, showing encouraging efficacy (33–50% ORR across cohorts), durable disease control (72% PFS at 18 months), and favorable safety profile (no dose-limiting toxicities, no treatment discontinuations). The company is advancing toward Phase 3 site preparation with expected initiation in 2027. This is a material clinical development milestone for a radiopharmaceutical company with a single lead program, affecting investor assessment of pipeline progress and regulatory pathway viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T14:55:58.783520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42235,"accession_number":"0001193125-26-429770","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Perspective Therapeutics announced updated interim Phase 1/2a clinical trial results for [212Pb]VMT-α-NET presented at ESMO Congress 2026, showing encouraging efficacy (33–50% ORR across cohorts), durable disease control (72% PFS at 18 months), and favorable safety profile (no dose-limiting toxicities, no treatment discontinuations). The company is advancing toward Phase 3 site preparation with expected initiation in 2027. This is a material clinical development milestone for a radiopharmaceutical company with a single lead program, affecting investor assessment of pipeline progress and regulatory pathway viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T14:55:58.783520+00:00","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-10-23"}]}